

---

## NOTIFICATION TO RESPOND

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, reviewing and collecting the data, and reviewing and editing the collection of information. An agency may not conduct or sponsor a collection of information, and a person may not respond to a collection of information unless it displays a current, valid OMB control number.

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden to Washington Headquarters Office of Management and Budget, Paperwork Project Director (0142-0046), Washington, DC 20503.

Send comments regarding this burden estimate or any other aspect of the burden of this collection of information, including suggestions for reducing the burden, to Washington Headquarters Office of Management and Budget, Paperwork Project Director (0142-0046), Washington, DC 20503. Do not return the completed form to this address.

---

---

OMB#: 0925-0600 EXP. DATE: 3/31/13

**IDENT OF ESTIMATED BURDEN**

ed to average sixty (60) minutes for this questionnaire, including the  
nd maintain the data needed, and complete and review the collection of  
is not required to respond to, a collection of information unless it

ect of this collection of information, including suggestions for reducing

. Bethesda, MD 20892-7974, ATTN: PRA (0925-0600).

---

# CTRP Trial Registration Batch Upload Specificatio

## About this Document

This document provides you with everything you need to know to upload clinical trial data to th

## Template Instructions

The Template Instructions worksheet provides detailed instructions for preparing y

## Sample Trial Data

The Sample Trial Data worksheet provides an example of what a typical batch uplc

**Note:** The worksheet that contains your trial data MUST always be the FIRST work

## Trial Data Pick List

The *Trial Data Pick List* worksheet contains sets of valid values for many of the dat  
The values are displayed in pick lists when you select an appropriate data element  
The pick lists have been provided to assist you in filling out these cells quickly and  
However, if you prefer, you can type the values instead.

**Note:** The drop-down lists will not work if you delete this worksheet.

## Trial Data Element Specifications

The specifications worksheet includes the following information:

- 1 Data elements
- 2 Order in which the data elements *must be* presented. The element orde
- 3 Data element requirements. Requirements differ for original, updated, a
- 4 Valid values. The system accepts only those values listed in this docum
- 5 Comments. Additional information that helps you to ensure successful

## NIH and NCI Values

The NIH & NCI Values worksheet provides all acceptable values for the following d

- 1 Funding Mechanisms
- 2 Institute Codes
- 3 NCI Division/Program Codes
- 4 NIH Institute Codes

## NCI Code Definitions

The NCI Division/Program Code Definitions worksheet lists the long form of each o

## **Country Codes**

The Country Codes worksheet lists the 3-letter country codes for all countries that :

## **State and Province Codes**

The State and Province Codes worksheet lists the 2- or 3-letter state/province/territ

## **Oversight Authorities**

The Oversight Authorities worksheet lists the names of oversight authorities for all |

## on for Complete Trials

ie CTRP Trial Registration system, including the following:

our data and uploading them to the system.

oad file looks like.

sheet (tab) in the file.

a elements in the (*Sample*) *Trial Data* worksheet.

cell.

accurately.

r is set up for you in columns in the *Sample Trial Data* tab.

nd amended submissions.

ent.

upload of your data.

ata elements:

of the division/program acronyms.

submit clinical trial data to the CTRP system.

tory codes for the United States, Canada, and Australia.

countries that submit clinical trial data to the CTRP system.

# How to Upload

## Before You Upload

Contact the CTRO

Note: Once you have

## Main Steps for

- 1 Prepare the
- 2 Prepare the
- 3 Upload your

## Preparing The

- 1 Ensure that
  - \* Interv
  - \* Comj
  - \* Amer
  - \* Upda
  - \* 100 t
  - \* Multij
  - \* Multij
  - \* Gene
  - \* Multij
  - \* Two
  - \* Two

2 Create a

3 Copy the  
Most cell:

4 Delete th

- 5 Click the  
Arrows a  
5a. If arrc  
5b. If no a

**You mus**

- \* List trial
- \* Do not c
- \* Conform
- \* Identify

- 6 Delete th

## Preparing T

- 1 Prepare a
- 2 To avoid  
For exam  
If using tr
- 3 Provide tl
- 4 Zip all tria  
The trial c

Note: Sor

## Uploading Y

- 1 Open yo
- 2 Follow th  
<https://wil>

# Upload Clinical Trial Data to the CTRP Trial Registration System

## Begin

Contact [ncictro@mail.nih.gov](mailto:ncictro@mail.nih.gov) to request approval for sending batch files to CTRP. Include your login name, first name, and last name. Once you have received approval, you do not have to request approval for subsequent uploads.

## Preparation for Uploading Your Data

Prepare the trial data file.

Prepare the trial documents Zip file.

Upload your files to the CTRP system via the NCI Trial Registration application batch upload web page at <https://trialregistration.nih.gov>

## Trial Data Files

Ensure that your trial conforms to the supported criteria. This template supports the following:

Conventional trials

Complete (Summary 4 Funding Sponsor Category is 'National', 'Externally Peer-Reviewed' or 'Institutional') trials

Amendments to complete CTRP trials with "Abstraction Verified Response" or "Abstraction Verified No Response"

Amendments to complete CTRP trials with the processing status "Accepted" and beyond

Multiple trials per data file

Multiple grants per submitted trial

Multiple IND/IDE per submitted trial

Multiple primary contacts for Responsible Party or Sponsor

Multiple "Other" trial identifiers

Multiple options for data submission: a) when the XML file for trial submission to ClinicalTrials.gov is required, and

Multiple options for providing person and organization-related information: a) PO-ID for the person or organization,

**Note:** You can request a list of CTRP persons and organizations along with PO-IDs from the CTRO at [ncictro@mail.nih.gov](mailto:ncictro@mail.nih.gov).

Or, you can use the search organization/person feature in the CTRP Trial Registration application to ascertain PO-IDs.

Download the new Excel spreadsheet (.xls) that will contain the mandatory and optional data for the trial(s) as specified in the template.

Click on the *Sample Trial Data* and *Trial Data Pick List* tabs to your new spreadsheet.

Fields on the *Sample Trial Data* tab for which there are a defined set of valid values have drop-down lists. These fields are highlighted in yellow.

Copy the sample data from the *Sample Trial Data* tab in your new spreadsheet. Optionally, you can rename the tabs in your spreadsheet.

cell in which you want to enter data.

are displayed whenever a drop-down list is available.

Options are displayed next to the cell, click the arrow and select the appropriate value from the drop-down list.

When arrows are displayed, enter the appropriate information using the valid values in this template.

### **Must adhere to the following requirements:**

Order of elements required for registration in the order specified in the *Trial Data Element Spec* tab in this spreadsheet. Do not change the spelling of data elements or valid values. Changes to spelling or to the order of the trial elements must conform to the valid values guidelines when entering trial data. Valid values for each of the trial elements, where applicable, must be unique to each trial uniquely. For example, append your cancer center unique trial identifier to the file name.

Use the *Trial Data Pick List* worksheet from your new file.

## **Trial Document Zip Files**

Upload a separate Zip file containing applicable trial documents (e.g. Protocol, IRB approval, Informed Consent, Patient Information Sheet). When overwriting existing files when the system extracts your latest upload, rename the document files if they are already present. For example, prefix files with a unique trial identifier such as XXXX\_document name.doc.

When using trial identification prefixes, ensure that each of a given trial's document file names is unique.

Include the document names (including their extensions) in the file containing the trial data. Up to seven (7) files can be included in a trial-related documents. Do not include pathnames in the Zip files.

The document Zip file that you intend to upload **MUST NOT** include folders or other Zip files. All trial-related documents must be included in the document Zip file.

Some elements will be ignored when updating existing CTRP trials via batch upload.

## **How to Upload Files**

Open your browser and navigate to the NCI Trial Registration application batch upload web page at <https://trials.nci.nih.gov/batch-upload>. See the instructions provided on the the Batch Trial Upload web page, or consult the user guide at:

<https://trials.nci.nih.gov/x/7qViAw>

names, and email address stored in your CTRP profile.

ov/registry/admin/batchUpload.action.

on  
ing statuses

XML file is not required.  
set of mandatory attributes for person or organization

nent.

to select valid values from a list. The sets of valid values for these drop-down lists are derive

the upload to fail. Similarly, the addition of new/extra trial elements will also cause a failure. are listed in the *Trial Data Element Spec* or other valid value tabs in this spreadsheet.

Sites, Change Memo) for the trials in the data file.

3. For detailed instructions and best practices for file preparation, refer to the CTRP Registrat

ed in one single trial record

ust be Word documents (.doc) or Adobe PDFs (.pdf). No other file types are currently accept

gistry/admin/batchUpload.action.

d from *Trial Data Pick List* worksheet.

ion Site User Guide at <https://wiki.nci.nih.gov/display/CTRP/Trial+Document+Preparation+for>

ed.

+Batch+Uploads.

	A	B	C	D	E	F
1	Unique Trial Identifier	Submission Type	NCI Trial Identifier	ClinicalTrials.gov XML Required?	Amendment Number	Amendment Date
2	10	O		Yes		
3	1000	A	NCI-2009-00001	Yes	A1	39938
4	2001	O		Yes		
5	3000	O		No		
6	4000	O		Yes		
7	5000	U	NCI-2009-00001			

	G	H	I	J	K
1	Lead Organization Trial Identifier	NCT	Other Trial Identifier	Title	Trial Type
2	53112	NCT000123	123;123-A	A Phase I study of Taxol in refractory leukemia in children	Interventional
3	1234	NCT00045		Phase III Study of Zoladex Adjuvant to Radiotherapy in Unfavorable Prognosis Carcinoma of the Prostate	Interventional
4	12345			A Phase I trial of Ifosfamide and Taxol in refractory Pelvic Malignancies	Interventional
5	65432			Phase III study of priming with granulocyte-macrophage colony stimulating factor (rhu-gm-csf) and of three induction regimens in adult patients (over 55) with acute non-lymphocytic leukemia	Interventional
6	1233			Phase III Comparison of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) vs. Doxorubicin and Cisplatin (AC) in Women with Advanced Primary or Recurrent Metastatic Carcinoma of the Uterine Endometrium	Interventional
7	12308	NCT009876	321-12	An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered with Oxaliplatin and Fluorouracil/Leucovorin in Patients with Advanced Solid Tumors	Interventional

	L	M	N	O	P	Q
1	Primary Purpose	[Primary Purpose] Additional Qualifier	[Primary Purpose] Other Text	Phase	Pilot Trial?	[Sponsor] Organization PO-ID
2	Treatment			I		
3	Treatment			III		
4	Treatment			I		654512
5	Treatment			III		
6	Other	Other	Laboratory	NA	Yes	87654
7	Treatment			I		

	R	S	T	U
1	[Sponsor] Organization Name	[Sponsor] Street Address	[Sponsor] City	[Sponsor] State/Province
2	Children's Oncology Group	2115 E Jefferson St	Rockville	MD
3	Radiation Therapy Oncology Group	200 Water Street	New York	NY
4				
5				
6				
7				

	V	W	X	Y
1	[Sponsor] Zip/Postal code	[Sponsor] Country	[Sponsor] Email Address	[Sponsor] Phone
2	20185	USA	<a href="mailto:test@cog.org">test@cog.org</a>	222-444-8888
3	22102	USA	<a href="mailto:mailto@rtog.com">mailto@rtog.com</a>	222-444-8888
4				
5				
6				
7				

	Z	AA	AB	AC	AD	AE
1	[Sponsor] TTY	[Sponsor] FAX	[Sponsor] URL	Responsible Party	Sponsor Contact Type	[Sponsor Contact] Title
2				PI		
3				Sponsor	Personal	
4				Sponsor	Generic	Clinical Study Department
5				PI	Personal	
6				Sponsor	Personal	
7				Sponsor	Generic	Director of Clinical Study Department

	AF	AG	AH	AI	AJ	AK
1	[Sponsor Contact] Person PO-ID	[Sponsor Contact] First Name	[Sponsor Contact] Middle Name	[Sponsor Contact] Last Name	[Sponsor Contact] Street Address	[Sponsor Contact] City
2						
3	23456					
4						
5						
6		Todd		Wright	400 Main St	Handerson
7						

	AL	AM	AN	AO	AP	AQ	AR
1	[Sponsor Contact] State/Province	[Sponsor Contact] Zip/Postal code	[Sponsor Contact] Country	[Sponsor Contact] Email Address	[Sponsor Contact] Phone	[Sponsor Contact] TTY	[Sponsor Contact] FAX
2							
3							
4				<a href="mailto:gog...">mailto@gog.</a>	240-345-4567		
5							
6	TN	20390	USA	<a href="mailto:twright@esoc...">twright@esoc</a>	607-123-1234		
7				<a href="mailto:twright@esoc...">twright@esoc</a>	607-123-1234		

	AS	AT	AU	AV	AW	AX
1	[Sponsor Contact] URL	[Lead Organization] Organization PO-ID	[Lead Organization] Name	[Lead Organization] Street Address	[Lead Organization] City	[Lead Organization] State/Province
2			Gynecologic Oncology Group	100 Main St	Fairfax	VA
3			Children's Oncology Group	2115 E Jefferson St	Rockville	MD
4			North Central Cancer Treatment Group	100 Meadow Rd	Hartford	CT
5		12345				
6			Children's Oncology Group	2115 E Jefferson St	Rockville	MD
7						

	AY	AZ	BA	BB	BC	BD
1	[Lead Organization] Zip/Postal code	[Lead Organization] Country	[Lead Organization] Email Address	[Lead Organization] Phone	[Lead Organization] TTY	[Lead Organization] FAX
2	22032	USA	<a href="mailto:test@cog.org">test@cog.org</a>	222-444-8888		
3	20185	USA	<a href="mailto:test@cog.org">test@cog.org</a>	222-444-8888		
4	33333	USA	<a href="mailto:test@cog.org">test@cog.org</a>	222-444-8888		
5						
6	20185	USA	<a href="mailto:test@cog.org">test@cog.org</a>	222-444-8888		
7						

	BE	BF	BG	BH	BI	BJ	BK
1	[Lead Organization] URL	[Lead Organization] Organization Type	[Principal Investigator] Person PO-ID	[Principal Investigator] First Name	[Principal Investigator] Middle Name	[Principal Investigator] Last Name	[Principal Investigator] Street Address
2		cooperative group	1234				
3		cooperative group		Miljenko	B	Pilepich	100 Village Hill Lane
4		cooperative group	87456				
5		cooperative group		Jacob	J	Rowe	100 Old Meadow Rd
6		cooperative group	45689				
7							

	BL	BM	BN	BO	BP	BQ	BR
1	[Principal Investigator] City	[Principal Investigator] State/Province	[Principal Investigator] Zip/Postal code	[Principal Investigator] Country	[Principal Investigator] Email Address	[Principal Investigator] Phone	[Principal Investigator] TTY
2							
3	Natick	MA	01760	USA	MPilepich@mednet.ucla.edu	111-111-1112	
4							
5	Houston	TX	33323	USA	rowe@rambam.health.gov.il	111-111-1114	
6							
7							

	BS	BT	BU	BV	BW	BX
1	[Principal Investigator] FAX	[Principal Investigator] URL	Summary 4 Funding Category	[Summary 4 Funding Sponsor/Source] Organization PO-ID	[Summary 4 Funding Sponsor/Source] Organization Name	[Summary 4 Funding Sponsor/Source] Street Address
2			Institutional		NCI	2115 E Jefferson
3			Institutional		NCI	2115 E Jefferson
4			Institutional		NCI	2115 E Jefferson
5			Institutional		NCI	2115 E Jefferson
6			Institutional		NCI	2115 E Jefferson
7			Institutional		NCI	2115 E Jefferson

	BY	BZ	CA	CB	CC	CD	CE
1	[Summary 4 Funding Sponsor/Source] City	[Summary 4 Funding Sponsor/Source] State/Province	[Summary 4 Funding Sponsor/Source] Zip/Postal code	[Summary 4 Funding Sponsor/Source] Country	[Summary 4 Funding Sponsor/Source] Email Address	[Summary 4 Funding Sponsor/Source] Phone	[Summary 4 Funding Sponsor/Source] TTY
2	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	
3	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	
4	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	
5	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	
6	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	
7	Rockville	MD	20852	USA	<a href="mailto:ctrp.org">mailto@ctrp.org</a>	111-111-1111	

	CF	CG	CH	CI	CJ
1	[Summary 4 Funding Sponsor/Source ] FAX	[Summary 4 Funding Sponsor/Source ] URL	Program Code	[NIH Grant] Funding Mechanism	[NIH Grant] Institute Code
2				F34	AG
3					
4			IM	K08;CO6	HV;AO
5					
6					
7			BR		

	CK	CL	CM	CN	CO	CP	CQ
1	[NIH Grant] Serial Number	[NIH Grant] NCI Division/Prog ram Code	Current Trial Status	Why Study Stopped?	Current Trial Status Date	Study Start Date	Study Start Date Type
2	72345	CTEP	Complete		8/1/2010	2/1/2009	Actual
3			Temporarily Closed to Accrual	Accrual target was reached for this phase of the study	8/2/2009	1/2/2009	Actual
4	97521;01234 5	CTEP;CTEP	In Review		8/3/2009	12/3/2010	Anticipated
5			Approved		8/4/2009	12/4/2010	Anticipated
6			Administrativ ely Complete	Closed prematurely	8/5/2009	1/5/2009	Actual
7			Approved		8/1/2009	12/1/2010	Anticipated

	CR	CS	CT	CU	CV	CW	CX
1	Primary Completion Date	Primary Completion Date Type	IND/IDE Type	IND/IDE Number	IND/IDE Grantor	IND/IDE Holder Type	[IND/IDE] NIH Institution
2	08/01/10	Actual					
3	10/02/11	Anticipated					
4	10/3/2011	Anticipated					
5	9/4/2012	Anticipated					
6	8/5/2009	Actual	IND;IND	67899;10,264	CDER;CDER	NIH;NCI	NIA;NA
7	12/1/2011	Anticipated					

	CY	CZ	DA	DB	DC	DD	DE
1	[IND/IDE] NCI Division /Program	[IND/IDE] Has Expanded Access?	[IND/IDE] Expanded Access Status	[IND/IDE] Exempt Indicator	Oversight Authority Country	Oversight Authority Organization Name	FDA Regulatory Information Indicator
2					United States	Federal Government	No
3					United States	Federal Government	No
4					United States	Food and Drug Administratio n	Yes
5							
6	NA;DCP	No;Yes	NA;Approved for marketing	Yes;Yes	United States	Federal Government	No
7					United States	Federal Government	No

	DF	DG	DH	DI
1	Section 801 Indicator	Delayed Posting Indicator	Data Monitoring Committee Appointed Indicator	Protocol Document File Name
2			Yes	protocol_document_T10.doc
3			Yes	protocol_document_T1000.doc
4	Yes	No	Yes	protocol_document_T2001.doc
5				3000_protocol_document.doc
6			Yes	4000_protocol_document.doc
7			Yes	

	DJ	DK	DL	DM
1	IRB Approval Document File Name	Participating Sites Document File Name	Informed Consent Document File Name	Other Trial Related Document File Name
2	IRB_Approval.doc	Participating_Sites_T10.xls	10_Informed_Consent.PDF	10_Other_document.doc
3	IRB_Approval_06082007.doc	Participating_Sites_T1000_new.xls		
4	IRB_Approval_T2001.doc	Participating_Sites_T2001.xls	Informed_Consent_T2001.PDF	Other_document_T2001.doc
5	3000_IRB_Approval.doc	3000_Participating_Sites.xls	3000_Informed_Consent.PDF	3000_Other_document.doc
6	4000_IRB_Approval.doc	4000_Participating_Sites.xls	4000_Informed_Consent.PDF	4000_Other_document.doc
7				

	DN	DO
1	Change Memo Document Name	Protocol Highlight Document Name
2		
3	Change_memo_doc.doc	
4		
5		
6		
7		

Submission Type	Yes_No	Trial Type	Primary Purpose	Primary Purpose Additional Quali
A	No	Interventional	Basic Science	Other
O	Yes	Observational	Diagnostic	
U			Health Service Research	
			Other	
			Prevention	
			Screening	
			Supportive Care	
			Treatment	

**Phase Country Cod State Code Responsible Party Sponsor Contact Type**

	0	ABW	AK	PI	Personal
I		AFG	AL	Sponsor	Generic
I/II		AGO	AR		
II		AIA	AZ		
II/III		ALB	CA		
III		AND	CO		
IV		ANT	CT		
NA		ARE	DE		
		ARG	FL		
		ARM	GA		
		ASM	HI		
		ATA	IA		
		ATF	ID		
		ATG	IL		
		AUS	IN		
		AUT	KS		
		AZE	KY		
		BDI	LA		
		BEL	MA		
		BEN	MD		
		BFA	ME		
		BGD	MI		
		BGR	MN		
		BHR	MO		
		BHS	MS		
		BIH	MT		
		BLR	NC		
		BLZ	ND		
		BMU	NE		
		BOL	NH		
		BRA	NJ		
		BRB	NM		
		BRN	NV		
		BTN	NY		
		BVT	OH		
		BWA	OK		
		CAF	OR		
		CAN	PA		
		CCK	RI		
		CHE	SC		
		CHL	SD		
		CHN	TN		
		CIV	TX		
		CMR	UT		
		COG	VA		
		COK	VT		
		COL	WA		
		COM	WI		

CPV	WV
CRI	WY
CUB	AB
CXR	BC
CYM	MB
CYP	NB
CZE	NL
DEU	NS
DJI	NT
DMA	NU
DNK	ON
DOM	PE
DZA	QC
ECU	SK
EGY	YT
ERI	ACT
ESH	NSW
ESP	NT
EST	QLD
ETH	SA
FIN	TAS
FJI	VIC
FLK	WA
FRA	
FRO	
FSM	
FXX	
GAB	
GBR	
GEO	
GHA	
GIB	
GIN	
GLP	
GMB	
GNB	
GNQ	
GRC	
GRD	
GRL	
GTM	
GUF	
GUM	
GUY	
HKG	
HMD	
HND	
HRV	
HTI	
HUN	

IDN  
IND  
IOT  
IRL  
IRN  
IRQ  
ISL  
ISR  
ITA  
JAM  
JOR  
JPN  
KAZ  
KEN  
KGZ  
KHM  
KIR  
KNA  
KOR  
KWT  
LAO  
LBN  
LBR  
LBY  
LCA  
LIE  
LKA  
LSO  
LTU  
LUX  
LVA  
MAC  
MAR  
MCO  
MDA  
MDG  
MDV  
MEX  
MHL  
MKD  
MLI  
MLT  
MMR  
MNG  
MNP  
MOZ  
MRT  
MSR  
MTQ  
MUS

MWI  
MYS  
MYT  
NAM  
NCL  
NER  
NFK  
NGA  
NIC  
NIU  
NLD  
NOR  
NPL  
NRU  
NZL  
OMN  
PAK  
PAN  
PCN  
PER  
PHL  
PLW  
PNG  
POL  
PRI  
PRK  
PRT  
PRY  
PYF  
QAT  
REU  
ROM  
RUS  
RWA  
SAU  
SDN  
SEN  
SGP  
SGS  
SHN  
SJM  
SLB  
SLE  
SLV  
SMR  
SOM  
SPM  
STP  
SUR  
SVK

SVN  
SWE  
SWZ  
SYC  
SYR  
TCA  
TCD  
TGO  
THA  
TJK  
TKL  
TKM  
TMP  
TON  
TTO  
TUN  
TUR  
TUV  
TWN  
TZA  
UGA  
UKR  
UMI  
URY  
USA  
UZB  
VAT  
VCT  
VEN  
VGB  
VIR  
VNM  
VUT  
WLF  
WSM  
YEM  
YUG  
ZAF  
ZAR  
ZMB  
ZWE

**Lead Organization Type****Summary 4 Funding Category NIH Grant Funding Mechanis**

Institution	National	B01
ordering group	Externally	B08
repository	Peer-Reviewed	B09
research based	Institutional	C06
cooperative group		D43
cancer center		D71
consortium		DP1
drug company		DP2
network		DP3
		E11
		F05
		F30
		F31
		F32
		F33
		F34
		F37
		F38
		G07
		G08
		G11
		G12
		G13
		G20
		G94
		H13
		H23
		H25
		H28
		H50
		H57
		H62
		H64
		H75
		H79
		HD4
		HR!
		I01
		K01
		K02
		K05
		K06
		K07
		K08
		K12
		K14
		K18
		K21

K22  
K23  
K24  
K25  
K26  
K30  
K99  
KD1  
KL1  
KL2  
L30  
L32  
L40  
L50  
L60  
M01  
N01  
N02  
N03  
N43  
N44  
P01  
P20  
P30  
P40  
P41  
P42  
P50  
P51  
P60  
P76  
PL1  
PN1  
PN2  
R00  
R01  
R03  
R04  
R06  
R08  
R13  
R15  
R17  
R18  
R21  
R24  
R25  
R30  
R33  
R34

R36  
R37  
R41  
R42  
R43  
R44  
R49  
R55  
R56  
R90  
RC1  
RC2  
RC3  
RC4  
RL1  
RL2  
RL5  
RL9  
RS1  
S06  
S10  
S11  
S21  
S22  
SC1  
SC2  
SC3  
T01  
T02  
T03  
T06  
T09  
T14  
T15  
T32  
T34  
T35  
T36  
T37  
T42  
T90  
TL1  
TU2  
U01  
U09  
U10  
U11  
U13  
U14  
U17

U18  
U19  
U1A  
U1Q  
U1S  
U1T  
U1V  
U21  
U22  
U23  
U24  
U27  
U2G  
U2R  
U30  
U32  
U34  
U36  
U38  
U41  
U42  
U43  
U44  
U45  
U47  
U48  
U49  
U50  
U51  
U52  
U53  
U54  
U55  
U56  
U57  
U58  
U59  
U60  
U61  
U62  
U65  
U66  
U75  
U79  
U81  
U82  
U83  
U84  
U87  
U88

U90  
UA1  
UC1  
UC2  
UC3  
UC6  
UC7  
UD1  
UE1  
UE2  
UH1  
UH2  
UH3  
UL1  
UR1  
UR3  
UR6  
UR8  
US3  
US4  
UT1  
UT2  
VF1  
X01  
X02  
X06  
X98  
Y01  
Y02  
Z01  
Z02

**NIH Grant Institute Cod NCI Division/Program Code****Current Trial Status**

AA	CCR	In Review
AE	CCT/CTB	Approved
AF	CTEP	Active
AG	DCB	Closed to Accrual
AI	DCCPS	Closed to Accrual and Intervention
AM	DCEG	Temporarily Closed to Accrual
AO	DTP	Temporarily Closed to Accrual and Interventi
AR	DCP	Complete
AT	DEA	Administratively Complete
BC	OD	Withdrawn
BX	OSB/SPORES	
CA	CIP	
CB	CDP	
CD	TRP	
CE	RRP	
CH	N/A	
CI		
CK		
CL		
CM		
CN		
CO		
CP		
CR		
CT		
CU		
CX		
DA		
DC		
DD		
DE		
DK		
DP		
EB		
EH		
EM		
EP		
ES		
EY		
FD		
GD		
GH		
GM		
GW		
HB		
HC		
HD		
HG		

HI  
HK  
HL  
HM  
HO  
HP  
HR  
HS  
HV  
HX  
HY  
IP  
JT  
LM  
MD  
MH  
MN  
NB  
NH  
NR  
NS  
NU  
OA  
OC  
OD  
OF  
OH  
OL  
OR  
PC  
PH  
PR  
PS  
RC  
RD  
RG  
RM  
RR  
RX  
SC  
SF  
SH  
SM  
SP  
SU  
TI  
TP  
TS  
TW  
VA

WC  
WH  
WT

**Date Type IND/IDE Type IND/IDE Grantor IND/IDE Holder Type**

Actual	IND	CDER	Investigator
Anticipated	IDE	CBER	Organization
		CDRH	Industry
			NIH
			NCI

on

## **NIH Institution**

NEI-National Eye Institute

NHLBI-National Heart, Lung, and Blood Institute

NHGRI-National Human Genome Research Institute

NIA-National Institute on Aging

NIAAA-National Institute on Alcohol Abuse and Alcoholism

NIAID-National Institute of Allergy and Infectious Diseases

NIAMS-National Institute of Arthritis and Musculoskeletal and Skin Diseases

NIBIB-National Institute of Biomedical Imaging and Bioengineering

NICHD-Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDCD-National Institute on Deafness and Other Communication Disorders

NIDCR-National Institute of Dental and Craniofacial Research

NIDDK-National Institute of Diabetes and Digestive and Kidney Diseases

NIDA-National Institute on Drug Abuse

NIEHS-National Institute of Environmental Health Sciences

NIGMS-National Institute of General Medical Sciences

NIMH-National Institute of Mental Health

NINDS-National Institute of Neurological Disorders and Stroke

NINR-National Institute of Nursing Research

NLM-National Library of Medicine

CIT-Center for Information Technology

CSR-Center for Scientific Review

FIC-John E. Fogarty International Center for Advanced Study in the Health Sciences

NCCAM-National Center for Complementary and Alternative Medicine

NCMHD-National Center on Minority Health and Health Disparities

NCRR-National Center for Research Resources (NCRR)

CC-NIH Clinical Center

OD-Office of the Director

**IND/IDE Expanded Access Status**

Available

No longer available

Temporarily not available

Approved for marketing

ment

Trial elements Order	Trial data element	Required for original submission
1	Unique Trial Identifier	Yes
2	Submission Type	Yes
3	NCI Trial Identifier	
4	ClinicalTrials.gov XML Required?	Yes
5	Amendment Number	
6	Amendment Date	
7	Lead Organization Trial Identifier	Yes

8	NCT	
9	Other Trial Identifier	
10	Title	Yes
11	Trial Type	Yes
12	Primary Purpose	Yes
13	[Primary Purpose] Additional Qualifier	Yes if Primary Purpose is 'Other'
14	[Primary Purpose] Other Text	Yes if Primary Purpose is 'Other'
15	Phase	Yes
16	Pilot Trial?	
17	[Sponsor] Organization PO-ID	PO-ID or all mandatory organization attributes are not NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
18	[Sponsor] Organization Name	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
19	[Sponsor] Street Address	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
20	[Sponsor] City	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'

21	[Sponsor] State/Province	Yes for US/Canada/Australia Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes' and for US/Canada/Australia
22	[Sponsor] Zip/Postal code	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
23	[Sponsor] Country	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
24	[Sponsor] Email Address	Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'
25	[Sponsor] Phone	
26	[Sponsor] TTY	
27	[Sponsor] FAX	
28	[Sponsor] URL	
29	Responsible Party	Yes if ClinicalTrials.gov XML Required? is set to 'Yes'
30	Sponsor Contact Type	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor
31	[Sponsor Contact] Title	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Generic'
32	[Sponsor Contact] Person PO-ID	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'. Sponsor's Contact PO-ID or all person-specific mandatory attributes must be provided
33	[Sponsor Contact] First Name	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
34	[Sponsor Contact] Middle Name	

35	[Sponsor Contact] Last Name	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
36	[Sponsor Contact] Street Address	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
37	[Sponsor Contact] City	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
38	[Sponsor Contact] State/Province	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL and for USA, Canada or Australia
39	[Sponsor Contact] Zip/Postal code	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
40	[Sponsor Contact] Country	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL
41	[Sponsor Contact] Email Address	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'
42	[Sponsor Contact] Phone	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'
43	[Sponsor Contact] TTY	
44	[Sponsor Contact] FAX	
45	[Sponsor Contact] URL	

46	[Lead Organization] Organization PO-ID	PO-ID or all mandatory organization specific attribute are required
47	[Lead Organization] Name	Yes if Lead Organization PO-ID is NULL
48	[Lead Organization] Street Address	Yes if Lead Organization PO-ID is NULL
49	[Lead Organization] City	Yes if Lead Organization PO-ID is NULL
50	[Lead Organization] State/Province	Yes for US/Canada/Australia and if Lead Organization PO-ID is NULL
51	[Lead Organization] Zip/Postal code	Yes if Lead Organization PO-ID is NULL
52	[Lead Organization] Country	Yes if Lead Organization PO-ID is NULL
53	[Lead Organization] Email Address	Yes if Lead Organization PO-ID is NULL
54	[Lead Organization] Phone	
55	[Lead Organization] TTY	
56	[Lead Organization] FAX	
57	[Lead Organization] URL	
58	[Lead Organization] Organization Type	
59	[Principal Investigator] Person PO-ID	PO-ID or all person-specific mandatory attributes
60	[Principal Investigator] First Name	Yes if Principal Investigator PO-ID is NULL
61	[Principal Investigator] Middle Name	
62	[Principal Investigator] Last Name	Yes if Principal Investigator PO-ID is NULL
63	[Principal Investigator] Street Address	Yes if Principal Investigator PO-ID is NULL
64	[Principal Investigator] City	Yes if Principal Investigator PO-ID is NULL
65	[Principal Investigator] State/Province	Yes for US/Canada/Australia and if Principal Investigator PO-ID is NULL

66	[Principal Investigator] Zip/Postal code	Yes if Principal Investigator PO-ID is NULL
67	[Principal Investigator] Country	Yes if Principal Investigator PO-ID is NULL
68	[Principal Investigator] Email Address	Yes if Principal Investigator PO-ID is NULL
69	[Principal Investigator] Phone	Yes if Principal Investigator PO-ID is NULL
70	[Principal Investigator] TTY	
71	[Principal Investigator] FAX	
72	[Principal Investigator] URL	
73	Summary 4 Funding Category	Yes
74	[Summary 4 Funding Sponsor/Source] Organization PO-ID	PO-ID or all mandatory organization specific attribute are required
75	[Summary 4 Funding Sponsor/Source] Organization Name	Yes if Organization PO-ID is NULL
76	[Summary 4 Funding Sponsor/Source] Street Address	Yes if Organization PO-ID is NULL
77	[Summary 4 Funding Sponsor/Source] City	Yes if Organization PO-ID is NULL
78	[Summary 4 Funding Sponsor/Source] State/Province	Yes if Organization PO-ID is NULL and for US/Canada/Australia
79	[Summary 4 Funding Sponsor/Source] Zip/Postal code	Yes if Organization PO-ID is NULL
80	[Summary 4 Funding Sponsor/Source ] Country	Yes if Organization PO-ID is NULL
81	[Summary 4 Funding Sponsor/Source ] Email Address	Yes if Organization PO-ID is NULL
82	[Summary 4 Funding Sponsor/Source ] Phone	
83	[Summary 4 Funding Sponsor/Source ] TTY	
84	[Summary 4 Funding Sponsor/Source ] FAX	
85	[Summary 4 Funding Sponsor/Source ] URL	
86	Program Code	

87	[NIH Grant] Funding Mechanism	Yes: if NIH grant exists
88	[NIH Grant] Institute Code	Yes: if NIH grant exists
89	[NIH Grant] Serial Number	Yes: if NIH grant exists
90	[NIH Grant] NCI Division/Program Code	Yes: if NIH grant exists
91	Current Trial Status	Yes
92	Why Study Stopped?	Yes if Current Trial Status is Withdrawn, Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention or Administratively Complete
93	Current Trial Status Date	Yes
94	Study Start Date	Yes

95	Study Start Date Type	Yes
96	Primary Completion Date	Yes
97	Primary Completion Date Type	Yes
98	IND/IDE Type	Yes: if IND/IDE trial
99	IND/IDE Number	Yes: if IND/IDE trial
100	IND/IDE Grantor	Yes: if IND/IDE trial
101	IND/IDE Holder Type	Yes: if IND/IDE trial

102	[IND/IDE] NIH Institution	Yes if IND/IDE trial AND (IND/IDE Holder Type) = NIH
103	[IND/IDE] NCI Division /Program	Yes if IND/IDE trial AND If (IND/IDE Holder Type) = NCI
104	[IND/IDE] Has Expanded Access?	Yes if IND/IDE trial
105	[IND/IDE] Expanded Access Status	If (Has Expanded Access?) = Yes
106	[IND/IDE] Exempt Indicator	Yes
107	Oversight Authority Country	Yes if ClinicalTrials.gov XML Required? is set to 'Yes'
108	Oversight Authority Organization Name	Yes ClinicalTrials.gov XML Required? is set to 'Yes'
109	FDA Regulatory Information Indicator	Yes ClinicalTrials.gov XML Required? is set to 'Yes'
110	Section 801 Indicator	Yes if FDA Regulatory Information Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'
111	Delayed Posting Indicator	Yes if section 801 Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'
112	Data Monitoring Committee Appointed Indicator	
113	Protocol Document File Name	Yes

114	IRB Approval Document File Name	Yes
115	Participating Sites Document File Name	
116	Informed Consent Document File Name	
117	Other Trial Related Document File Name	
118	Change Memo Document Name	

119

Protocol Highlight Document  
Name

--	--	--

Required for amendment	Required for update	Valid Values
Yes	Yes	
Yes	Yes	O, A, U
Yes	Yes	
Yes		Yes, No
Yes		
Yes		

Yes		Max 4000 characters
Yes	Yes	Interventional, Observational
Yes	Yes	Treatment, Prevention, Supportive Care, Screening, Diagnostic, Health Service Research, Basic Science, Other
Yes if Primary Purpose is 'Other'	Yes if Primary Purpose is 'Other'	Other
Yes if Primary Purpose is 'Other'	Yes if Primary Purpose is 'Other'	
Yes	Yes	0, I, I/II, II, II/III, III, IV, NA,
		Yes, No
PO-ID or all mandatory organization attributes are not NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		

Yes for US/Canada/Australia Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes' and for US/Canada/Australia		2-letter state/province code required for US/Canada, 2-3 letter code required for Australia
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		3-letter country code required
Yes if Sponsor's PO-ID is NULL AND if 'ClinicalTrials.gov XML Required?'='Yes'		
Yes if ClinicalTrials.gov XML Required? is set to 'Yes'		PI, Sponsor
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party value is Sponsor	Personal, Generic
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Generic'	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Generic'	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'. Sponsor's Contact PO-ID or all person-specific mandatory attributes must be provided	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'. Sponsor's Contact PO-ID or all person-specific mandatory attributes must be provided	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	

Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL and for USA, Canada or Australia	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL and for USA, Canada or Australia	2-letter state/province code required for US/Canada, 2-3 letter code required for Australia
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal' and Sponsor's Contact PO-ID is NULL	3-letter country code required
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'	
Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'	Yes if 'ClinicalTrials.gov XML Required?'='Yes' and if Responsible Party is Sponsor and Sponsor Contact Type is 'Personal'	

PO-ID or all mandatory organization specific attribute are required		
Yes if Lead Organization PO-ID is NULL		
Yes if Lead Organization PO-ID is NULL		
Yes if Lead Organization PO-ID is NULL		
Yes for US/Canada/Australia and if Lead Organization PO-ID is NULL		2-letter state/province code required for US/Canada, 2-3 letter code required for Australia
Yes if Lead Organization PO-ID is NULL		
Yes if Lead Organization PO-ID is NULL		3-letter country code required
Yes if Lead Organization PO-ID is NULL		
		Institution, ordering group, repository, research based,
PO-ID or all person-specific mandatory attributes		
Yes if Principal Investigator PO-ID is NULL		
Yes if Principal Investigator PO-ID is NULL		
Yes if Principal Investigator PO-ID is NULL		
Yes if Principal Investigator PO-ID is NULL		
Yes for US/Canada/Australia and if Principal Investigator PO-ID is NULL		2-letter state/province code required for US/Canada, 2-3 letter code required for Australia

Yes if Principal Investigator PO-ID is NULL		
Yes if Principal Investigator PO-ID is NULL		3-letter country code required
Yes if Principal Investigator PO-ID is NULL		
Yes if Principal Investigator PO-ID is NULL		
Yes	Yes	National, Externally Peer-Reviewed, Institutional
PO-ID or all mandatory organization specific attribute are required	PO-ID or all mandatory organization specific attribute are required	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	
Yes if Organization PO-ID is NULL and for US/Canada/Australia	Yes if Organization PO-ID is NULL and for US/Canada/Australia	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	
Yes if Organization PO-ID is NULL	Yes if Organization PO-ID is NULL	

Yes: if NIH grant exists	Yes: if NIH grant exists	Refer Funding Mechanism in Valid Values worksheet.
Yes: if NIH grant exists	Yes: if NIH grant exists	Refer Institute Code in Valid Values worksheet.
Yes: if NIH grant exists	Yes: if NIH grant exists	format: 5 or 6 digits
Yes: if NIH grant exists	Yes: if NIH grant exists	Refer NCI Division/Program Code in Valid Values worksheet. Specify only the code.
Yes	Yes	In Review, Approved, Active, Closed to Accrual, Closed to Accrual and Intervention , Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention, Complete, Administratively Complete are
Yes if Current Trial Status is Withdrawn, Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention or Administratively Complete	Yes if Current Trial Status is Withdrawn, Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention or Administratively Complete	
Yes	Yes	
Yes	Yes	

Yes	Yes	Actual, Anticipated
Yes	Yes	
Yes	Yes	Actual, Anticipated
Yes: if IND/IDE trial	Yes: if IND/IDE trial	IND, IDE
Yes: if IND/IDE trial	Yes: if IND/IDE trial	
Yes: if IND/IDE trial	Yes: if IND/IDE trial	CDER, CBER, CDRH
Yes: if IND/IDE trial	Yes: if IND/IDE trial	Investigator, Organization, Industry, NIH, NCI

Yes If IND/IDE trial AND (IND/IDE Holder Type) = NIH	Yes If IND/IDE trial AND (IND/IDE Holder Type) = NIH	Refer NIH Institution in Valid Values worksheet.
Yes if IND/IDE trial AND If (IND/IDE Holder Type) = NCI	Yes if IND/IDE trial AND If (IND/IDE Holder Type) = NCI	Refer NCI Division/Program Code in Valid Values worksheet.
Yes if IND/IDE trial	Yes if IND/IDE trial	Yes, No
If (Has Expanded Access?) = Yes	If (Has Expanded Access?) = Yes	Available, No longer available, Temporarily not available, Approved for marketing
		Yes, No
Yes if ClinicalTrials.gov XML Required? is set to 'Yes'	Yes if ClinicalTrials.gov XML Required? is set to 'Yes'	see Oversight Authority tab
Yes ClinicalTrials.gov XML Required? is set to 'Yes'	Yes ClinicalTrials.gov XML Required? is set to 'Yes'	see Oversight Authority tab
Yes ClinicalTrials.gov XML Required? is set to 'Yes'	Yes ClinicalTrials.gov XML Required? is set to 'Yes'	Yes, No
Yes if FDA Regulatory Information Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'	Yes if FDA Regulatory Information Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'	Yes, No
Yes if section 801 Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'	Yes if section 801 Indicator is 'Yes' and ClinicalTrials.gov XML Required? is set to 'Yes'	Yes, No
		Yes, No
Yes		

Yes

Yes

--	--	--

## Comments

O - original submission (including the first submission to CTRP); A - amendment submission to the already published trial in CTRP; U - update to the CTRP trial. Amendment submission can be accepted only if the trial processing status is 'Abstraction Verified Response' or 'Abstraction Verified No Response'. Update can be submitted for trials that have been accepted or have processing status other than 'Submitted' and 'Rejected'. See Processing Status Transition tab for information about trial processing statuses

This element is applicable to amendment submission and update to the CTRP trials only. This is the trial identifier assigned by the CTRP. Amendment can only be accepted for trials that have 'Abstraction Verified Response' or 'Abstraction Verified No Response' processing status in CTRP. Update can be submitted for trials that have 'Accepted' status and above.

Indicates whether XML generation for trial submitting in ClinicalTrials.gov is required. If Indicator is assigned to 'No', responsible Party information and Regulatory Information is not required (will be ignored if provided). This value is ignored in update submission

This element is applicable to amendment submission only. Use amendment number that is recorded in user's system.

This element is applicable to amendment submission only. Use date of amendment as documented in the amended protocol document . Format mm/dd/yyyy.

AS IS in the protocol document & assigned by the lead organization (unique in the lead organization system)

Unique identifier assigned to the published trials in PRS (ClinicalTrials.gov)

If more than one exists, provide them in one column separated with semicolon (;)

Title from the protocol document

Currently only Interventional trials are accepted

Use value 'Other' if Primary Purpose value is 'Other' (this applies to interventional trials only)

Provide description if Primary Purpose is 'Other' (col 13)

Will be recorded only if Phase value is NA.  
Default: No

Include Phone Extension if any in the same field. Use XXX-XXX-XXXX format for USA and Canada
Ignored if ClinicalTrials.gov XML Required? is set to 'No'
Used for defining contact type for the Responsible Party Sponsor (see 27)
Applicable to the Responsible Party=Sponsor Generic Contact only
Applicable to the Responsible Party=Sponsor Personal Contact only
Applicable to the Responsible Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Applicable to the Responsible  
Party=Sponsor Personal Contact only

Include Phone Extension if any in the  
same field. Use XXX-XXX-XXXX format  
for USA and Canada




Include Phone Extension if any in the same field. Use XXX-XXX-XXXX format for USA and Canada
Provide PO-ID or all organization related mandatory attributes
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Provide if PO-ID is NULL
Include Phone Extension if any in the same field. Use XXX-XXX-XXXX format for USA and Canada
Summary 4 element, no LOV exists, codes are specific to cancer centers

If more than one grant is recorded provide this value for all grants separated by semicolon (;)
If more than one grant is recorded provide this value for all grants separated by semicolon (;)
If more than one grant is recorded provide this value for all grants separated by semicolon (;)
Defaults to N/A if not specified. If more than one grant is recorded provide this value for all grants separated by semicolon (;)
1) Trials with current trial status 'Withdrawn' are not accepted for the original submission. 2) Submission of amendment or update to existing study with Completed, Administratively Completed, Withdrawn and Disapproved <u>current trial status are not accepted.</u> 3)
Mandatory if Current Trial Status is Withdrawn, Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention or Administratively Complete
Date when the status has come in effect. Format: mm/dd/yyyy
Date that enrollment to the protocol begins. Format: mm/dd/yyyy

Only current/past date (in respect to batch upload date) is accepted for actual type and only future date is accepted for anticipated type. 'Anticipated' type is valid for 'In Review' and 'Approved' and 'Withdrawn' current trial status only. 'Actual' type is valid for any other current trial status besides 'In Review', 'Approved' and 'Withdrawn'. For more information check State-Dates tab in this file.

Date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical trial concluded according to the prespecified protocol or was terminated. Format: mm/dd/yyyy

Only current/past date (in respect to batch upload date) is accepted for actual type and only future date is accepted for anticipated type. 'Actual' type is valid for 'Administratively Complete' or 'Complete' current trial statuses only. 'Anticipated' type is valid for any other current trial status besides 'Administratively Complete' or 'Complete'. For more information check State-Dates tab in this file.

If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;).

If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;)

If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;)

If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;)

<p>If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;). If NIH institution is not applicable to a single IND/IDE, provide NA as replacement for the value</p>
<p>If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;). If NCI division/program is not applicable to a single IND/IDE, provide NA as replacement for the value</p>
<p>If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;).</p>
<p>If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;). If expanded access is not applicable to a single IND/IDE, provide NA as replacement for the value</p>
<p>If more than one IND/IDE is recorded provide this value for all IND/IDE separated by semicolon (;). Default: 'No'</p>
<p>Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>Must be 'Yes' if trial includes IND/IDE. Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>Must be not NULL if FDA Regulatory Information Indicator is 'Yes'. Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>Must be not NULL if section 801 Indicator is 'Yes'. Delayed Posting Indicator is applicable only to study that includes device intervention. Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>Ignored if ClinicalTrials.gov XML Required? is set to 'No'</p>
<p>1) Include file extension. 2) If you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name). 3) Submit amended protocol for amendment submission.</p>

1) Include file extension. 2) if you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name). 3) Submit dummy file if IRB approval is not required with the statement 'IRB' approval is not required'. 4) Submit dummy file with the following info: name of Review Board (address, phone, email) and Board Affiliation name in case of pre-IRB approved studies submission. 5) One IRB Approval is only needed.

1) Include file extension. 2) if you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name). 3) Required if case of multi-site trial and if the participation sites information is not included in the protocol document. 4) If participating site changes (recruitment status, program code) or collaborator's info change occur, submit this document for amendment or update

1) Required if is not included in the protocol document. 2) Include file extension. 3) if you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name).

1) Include file extension. 2) if you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name).

1) This element is applicable to the amendment only and includes the changes that occurred in the protocol document due to amendment. 2) Include file extension. 3) if you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name).

1) This element is applicable to the amendment only and includes the protocol document with highlighted changes from the previous version. 2) Include file extension. 3) If you have at least two files with the same name, rename files (ex. prefix unique trial identifier to document name).

NOTE: These are the valid values for the data elements. Although they are presented in ve

Funding Mechanism	Institute Code	NCI Division/Program Code
B01	AA	CCR
B08	AE	CTEP
B09	AF	CIP
C06	AG	CDP
DP1	AI	CCT/CTB
DP2	AM	DCB
DP3	AO	DCCPS
D43	AR	DCEG
D71	AT	DTP
E11	BC	DCP
F05	BX	DEA
F30	CA	OD
F31	CB	OSB/SPOREs
F32	CD	TRP
F33	CE	RRP
F34	CH	N/A
F37	CI	
F38	CK	
G07	CL	
G08	CM	
G11	CN	
G12	CO	
G13	CP	
G20	CR	

G94
HD4
HR!
H13
H23
H25
H28
H50
H57
H62
H64
H75
H79
I01
KD1
KL1
KL2
K01
K02
K05
K06
K07
K08
K12
K14
K18
K21
K22
K23
K24
K25
K26
K30
K99
L30
L32
L40
L50
L60
M01
N01
N02
N03

CT
CU
CX
DA
DC
DD
DE
DK
DP
EB
EH
EM
EP
ES
EY
FD
GD
GH
GM
GW
HB
HC
HD
HG
HI
HK
HL
HM
HO
HP
HR
HS
HV
HX
HY
IP
JT
LM
MD
MH
MN
NB
NH
NR

N43
N44
PL1
PN1
PN2
P01
P20
P30
P40
P41
P42
P50
P51
P60
P76
RC1
RC2
RC3
RC4
RL1
RL2
RL5
RL9
RS1
R00
R01
R03
R04
R06
R08
R13
R15
R17
R18
R21
R24
R25
R30
R33
R34
R36
R37
R41
R42
R43

NS
NU
OA
OC
OD
OF
OH
OL
OR
PC
PH
PR
PS
RD
RX
SC
SF
SH
SM
SP
SU
TI
TP
TS
WH
RC
RG
RM
RR
TW
WT
VA
WC

R44
R49
R55
R56
R90
SC1
SC2
SC3
S06
S10
S11
S21
S22
TL1
TU2
T01
T02
T03
T06
T09
T14
T15
T32
T34
T35
T36
T37
T42
T90
UA1
UC1
UC2
UC3
UC6
UC7
UD1
UE1
UE2
UH1
UH2
UH3
UL1
UR1
UR3
UR6

UR8
US3
US4
UT1
UT2
U01
U09
U10
U11
U13
U14
U17
U18
U19
U1A
U1Q
U1S
U1T
U1V
U21
U22
U23
U24
U27
U2G
U2R
U30
U32
U34
U36
U38
U41
U42
U43
U44
U45
U47
U48
U49
U50
U51
U52
U53
U54
U55

U56
U57
U58
U59
U60
U61
U62
U65
U66
U75
U79
U81
U82
U83
U84
U87
U88
U90
VF1
X01
X02
X06
X98
Y01
Y02
Z01
Z02

artical format, there is no correlation between the columns.

<b>NIH Institution</b>	
NEI-National Eye Institute	
NHLBI-National Heart, Lung, and Blood Institute	
NHGRI-National Human Genome Research Institute	
NIA-National Institute on Aging	
NIAAA-National Institute on Alcohol Abuse and Alcoholism	
NIAID-National Institute of Allergy and Infectious Diseases	
NIAMS-National Institute of Arthritis and Musculoskeletal and Skin Diseases	
NIBIB-National Institute of Biomedical Imaging and Bioengineering	
NICHD-Eunice Kennedy Shriver National Institute of Child Health and Human Development	
NIDCD-National Institute on Deafness and Other Communication Disorders	
NIDCR-National Institute of Dental and Craniofacial Research	
NIDDK-National Institute of Diabetes and Digestive and Kidney Diseases	
NIDA-National Institute on Drug Abuse	
NIEHS-National Institute of Environmental Health Sciences	
NIGMS-National Institute of General Medical Sciences	
NIMH-National Institute of Mental Health	
NINDS-National Institute of Neurological Disorders and Stroke	
NINR-National Institute of Nursing Research	
NLM-National Library of Medicine	
CIT-Center for Information Technology	
CSR-Center for Scientific Review	
FIC-John E. Fogarty International Center for Advanced Study in the Health Sciences	
NCCAM-National Center for Complementary and Alternative Medicine	
NCMHD-National Center on Minority Health and Health Disparities	

NCRR-National Center for Research Resources (NCRR
--

CC-NIH Clinical Center
------------------------

OD-Office of the Director
---------------------------

NCI Division/Program Code
CCR
CCT/CTB
CTEP
DCB
DCCPS
DCEG
DTP
DCP
DEA
OD
OSB/SPOREs
CIP
CDP
TRP
RRP
N/A

<b>Definition</b>
Center for Cancer Research
Center for Cancer Training / Cancer Training Branch
Cancer Therapy Evaluation Program
Division of Cancer Biology
Division of Cancer Control and Population Sciences
Division of Cancer Epidemiology and Genetics
Developmental Therapeutics Program
Division of Cancer Prevention
Division of Extramural Activities
Office of the Director, NCI, NIH
Organ Systems Branch (OSB) /Specialized Programs of Research Excellence (SPOREs)
Cancer Imaging Program
Cancer Diagnosis Program
Translational Research Program
Radiation Research Program
Not applicable

<b>Country</b>	<b>3-letter code</b>
AFGHANISTAN	AFG
ALBANIA	ALB
ALGERIA	DZA
AMERICAN SAMOA	ASM
ANDORRA	AND
ANGOLA	AGO
ANGUILLA	AIA
ANTARCTICA	ATA
ANTIGUA AND BARBUDA	ATG
ARGENTINA	ARG
ARMENIA	ARM
ARUBA	ABW
AUSTRALIA	AUS
AUSTRIA	AUT
AZERBAIJAN	AZE
BAHAMAS	BHS
BAHRAIN	BHR
BANGLADESH	BGD
BARBADOS	BRB
BELARUS	BLR
BELGIUM	BEL
BELIZE	BLZ
BENIN	BEN
BERMUDA	BMU
BHUTAN	BTN
BOLIVIA	BOL
BOSNIA AND HERZEGOWINA	BIH
BOTSWANA	BWA
BOUVET ISLAND	BVT
BRAZIL	BRA
BRITISH INDIAN OCEAN TERRITORY	IOT
BRUNEI DARUSSALAM	BRN
BULGARIA	BGR
BURKINA FASO	BFA
BURUNDI	BDI
CAMBODIA	KHM
CAMEROON	CMR
CANADA	CAN
CAPE VERDE	CPV
CAYMAN ISLANDS	CYM
CENTRAL AFRICAN REPUBLIC	CAF
CHAD	TCD
CHILE	CHL
CHINA	CHN

CHRISTMAS ISLAND	CXR
COCOS (KEELING) ISLANDS	CCK
COLOMBIA	COL
COMOROS	COM
CONGO	COG
COOK ISLANDS	COK
COSTA RICA	CRI
COTE D'IVOIRE	CIV
CROATIA (local name: Hrvatska)	HRV
CUBA	CUB
CYPRUS	CYP
CZECH REPUBLIC	CZE
DENMARK	DNK
DJIBOUTI	DJI
DOMINICA	DMA
DOMINICAN REPUBLIC	DOM
EAST TIMOR	TMP
ECUADOR	ECU
EGYPT	EGY
EL SALVADOR	SLV
EQUATORIAL GUINEA	GNQ
ERITREA	ERI
ESTONIA	EST
ETHIOPIA	ETH
FALKLAND ISLANDS (MALVINAS)	FLK
FAROE ISLANDS	FRO
FIJI	FJI
FINLAND	FIN
FRANCE	FRA
FRANCE, METROPOLITAN	FXX
FRENCH GUIANA	GUF
FRENCH POLYNESIA	PYF
FRENCH SOUTHERN TERRITORIES	ATF
GABON	GAB
GAMBIA	GMB
GEORGIA	GEO
GERMANY	DEU
GHANA	GHA
GIBRALTAR	GIB
GREECE	GRC
GREENLAND	GRL
GRENADA	GRD
GUADELOUPE	GLP
GUAM	GUM
GUATEMALA	GTM
GUINEA	GIN

GUINEA-BISSAU	GNB
GUYANA	GUY
HAITI	HTI
HEARD AND MC DONALD ISLANDS	HMD
HOLY SEE (VATICAN CITY STATE)	VAT
HONDURAS	HND
HONG KONG	HKG
HUNGARY	HUN
ICELAND	ISL
INDIA	IND
INDONESIA	IDN
IRAN (ISLAMIC REPUBLIC OF)	IRN
IRAQ	IRQ
IRELAND	IRL
ISRAEL	ISR
ITALY	ITA
JAMAICA	JAM
JAPAN	JPN
JORDAN	JOR
KAZAKHSTAN	KAZ
KENYA	KEN
KIRIBATI	KIR
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF	PRK
KOREA, REPUBLIC OF	KOR
KUWAIT	KWT
KYRGYZSTAN	KGZ
LAO PEOPLE'S DEMOCRATIC REPUBLIC	LAO
LATVIA	LVA
LEBANON	LBN
LESOTHO	LSO
LIBERIA	LBR
LIBYAN ARAB JAMAHIRIYA	LBY
LIECHTENSTEIN	LIE
LITHUANIA	LTU
LUXEMBOURG	LUX
MACAU	MAC
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC	MKD
MADAGASCAR	MDG
MALAWI	MWI
MALAYSIA	MYS
MALDIVES	MDV
MALI	MLI
MALTA	MLT
MARSHALL ISLANDS	MHL
MARTINIQUE	MTQ
MAURITANIA	MRT

MAURITIUS	MUS
MAYOTTE	MYT
MEXICO	MEX
MICRONESIA, FEDERATED STATES OF	FSM
MOLDOVA, REPUBLIC OF	MDA
MONACO	MCO
MONGOLIA	MNG
MONTSERAT	MSR
MOROCCO	MAR
MOZAMBIQUE	MOZ
MYANMAR	MMR
NAMIBIA	NAM
NAURU	NRU
NEPAL	NPL
NETHERLANDS	NLD
NETHERLANDS ANTILLES	ANT
NEW CALEDONIA	NCL
NEW ZEALAND	NZL
NICARAGUA	NIC
NIGER	NER
NIGERIA	NGA
NIUE	NIU
NORFOLK ISLAND	NFK
NORTHERN MARIANA ISLANDS	MNP
NORWAY	NOR
OMAN	OMN
PAKISTAN	PAK
PALAU	PLW
PANAMA	PAN
PAPUA NEW GUINEA	PNG
PARAGUAY	PRY
PERU	PER
PHILIPPINES	PHL
PITCAIRN	PCN
POLAND	POL
PORTUGAL	PRT
PUERTO RICO	PRI
QATAR	QAT
REUNION	REU
ROMANIA	ROM
RUSSIAN FEDERATION	RUS
RWANDA	RWA
SAINT KITTS AND NEVIS	KNA
SAINT LUCIA	LCA
SAINT VINCENT AND THE GRENADINES	VCT
SAMOA	WSM

SAN MARINO	SMR
SAO TOME AND PRINCIPE	STP
SAUDI ARABIA	SAU
SENEGAL	SEN
SEYCHELLES	SYC
SIERRA LEONE	SLE
SINGAPORE	SGP
SLOVAKIA (Slovak Republic)	SVK
SLOVENIA	SVN
SOLOMON ISLANDS	SLB
SOMALIA	SOM
SOUTH AFRICA	ZAF
SOUTH GEORGIA AND THE SOUTH SANDWICH IS	SGS
SPAIN	ESP
SRI LANKA	LKA
ST. HELENA	SHN
ST. PIERRE AND MIQUELON	SPM
SUDAN	SDN
SURINAME	SUR
SVALBARD AND JAN MAYEN ISLANDS	SJM
SWAZILAND	SWZ
SWEDEN	SWE
SWITZERLAND	CHE
SYRIAN ARAB REPUBLIC	SYR
TAIWAN, PROVINCE OF CHINA	TWN
TAJIKISTAN	TJK
TANZANIA, UNITED REPUBLIC OF	TZA
THAILAND	THA
TOGO	TGO
TOKELAU	TKL
TONGA	TON
TRINIDAD AND TOBAGO	TTO
TUNISIA	TUN
TURKEY	TUR
TURKMENISTAN	TKM
TURKS AND CAICOS ISLANDS	TCA
TUVALU	TUV
UGANDA	UGA
UKRAINE	UKR
UNITED ARAB EMIRATES	ARE
UNITED KINGDOM	GBR
UNITED STATES	USA
UNITED STATES MINOR OUTLYING ISLANDS	UMI
URUGUAY	URY
UZBEKISTAN	UZB
VANUATU	VUT

VENEZUELA	VEN
VIET NAM	VNM
VIRGIN ISLANDS (BRITISH)	VGB
VIRGIN ISLANDS (U.S.)	VIR
WALLIS AND FUTUNA ISLANDS	WLF
WESTERN SAHARA	ESH
YEMEN	YEM
YUGOSLAVIA	YUG
ZAIRE	ZAR
ZAMBIA	ZMB
ZIMBABWE	ZWE

Country	Country 3-letter cod	State/Province
UNITED STATES	USA	Alabama
		Alaska
		Arizona
		Arkansas
		California
		Colorado
		Connecticut
		Delaware
		Florida
		Georgia
		Hawaii
		Idaho
		Illinois
		Indiana
		Iowa
		Kansas
		Kentucky
		Louisiana
		Maine
		Maryland
		Massachusetts
		Michigan
		Minnesota
		Mississippi
		Missouri
		Montana
		Nebraska
		Nevada
		New Hampshire
		New Jersey
		New Mexico
		New York
		North Carolina
		North Dakota
		Ohio
		Oklahoma
		Oregon
		Pennsylvania
		Rhode Island
		South Carolina
		South Dakota
		Tennessee
		Texas
		Utah

Vermont  
Virginia  
Washington  
West Virginia  
Wisconsin  
Wyoming

CANADA

CAN

Alberta  
British Columbia  
Manitoba  
New Brunswick  
Newfoundland and Labrador  
Northwest Territories  
Nova Scotia  
Nunavut  
Ontario  
Prince Edward Island  
Quebec  
Saskatchewan  
Yukon

AUSTRALIA

AUT

Australian Capital Territory  
New South Wales  
Northern Territory  
Queensland  
South Australia  
Tasmania  
Victoria  
Western Australia

## 2-3 letter state/province cod Old values

AL  
AK  
AZ  
AR  
CA  
CO  
CT  
DE  
FL  
GA  
HI  
ID  
IL  
IN  
IA  
KS  
KY  
LA  
ME  
MD  
MA  
MI  
MN  
MS  
MO  
MT  
NE  
NV  
NH  
NJ  
NM  
NY  
NC  
ND  
OH  
OK  
OR  
PA  
RI  
SC  
SD  
TN  
TX  
UT

VT  
VA  
WA  
WV  
WI  
WY

AB  
BC  
MB  
NB  
NL  
NT  
NS  
NU  
ON  
PE  
QC  
SK  
YT

ACT  
NSW  
NT  
QLD  
SA  
TAS  
VIC  
WA

**Oversight Authority  
Country**

Afghanistan  
Algeria  
Argentina  
Argentina

Australia  
Australia  
Australia  
Austria  
Austria  
Austria  
Austria  
Bangladesh  
Bangladesh  
Bangladesh  
Belarus  
Belgium  
Belgium  
Belgium  
Belgium  
Belgium

Bolivia  
Bolivia  
Brazil  
Brazil  
Brazil  
Bulgaria  
Bulgaria  
Burkina Faso  
Burkina Faso  
Cambodia  
Cameroon  
Canada  
Canada  
Canada  
Canada  
Chile  
Chile  
China  
China  
China  
Colombia

Colombia  
Croatia

Croatia  
Czech Republic  
Czech Republic  
Denmark  
Denmark  
Denmark  
Denmark  
Denmark  
Denmark  
Denmark  
Denmark  
Dominican Republic

Ecuador  
Egypt  
Egypt  
Estonia  
Ethiopia  
Finland  
Finland  
Finland  
France  
France  
France  
France  
France  
France  
France  
Gambia  
Gambia  
Georgia  
Germany  
Germany  
Germany  
Germany  
Germany  
Ghana  
Ghana  
Greece  
Greece  
Greece  
Guinea-Bissau  
Hong Kong  
Hong Kong  
Hong Kong  
Hungary  
Iceland  
Iceland  
India  
India

India  
India  
India  
India  
India  
Ireland  
Ireland  
Ireland  
Israel  
Israel  
Israel  
Israel  
Italy  
Italy  
Italy  
Italy  
Italy  
Italy  
Jamaica  
Japan  
Japan  
Japan  
Japan  
Japan  
Jordan  
Kazakhstan  
Kenya  
Kenya  
Kenya  
Latvia  
Lebanon  
Lebanon  
Liechtenstein  
Lithuania  
Lithuania  
Macedonia  
Malawi  
Malawi  
Malaysia  
Mali  
Mauritius  
Mexico  
Mexico  
Mexico  
Mexico  
Mexico  
Mexico  
Morocco

Mozambique  
Netherlands

Netherlands  
Netherlands  
Netherlands  
Netherlands  
New Zealand  
New Zealand  
New Zealand  
New Zealand  
New Zealand

Nigeria

Norway

Norway

Norway

Norway

Norway

Norway

Pakistan

Pakistan

Panama

Peru

Peru

Peru

Philippines

Philippines

Poland

Poland

Poland

Poland

Portugal

Portugal

Portugal

Romania

Romania

Saudi Arabia

Saudi Arabia

Senegal

Serbia

Sierra Leone

Singapore

Singapore

Singapore

Slovenia

Slovenia

South Africa

South Africa  
South Africa  
Spain  
Spain  
Spain  
Spain  
Spain  
Sri Lanka  
Sudan  
Sweden  
Sweden  
Sweden  
Sweden  
Sweden  
Switzerland  
Switzerland  
Switzerland  
Switzerland  
Taiwan  
Taiwan  
Taiwan  
Tanzania  
Tanzania  
Tanzania  
Thailand  
Thailand  
Thailand  
Thailand  
Tunisia  
Tunisia  
Turkey  
Turkey  
Uganda  
Uganda  
Uganda  
Ukraine  
Ukraine  
United Arab Emirates  
United Arab Emirates

United Kingdom  
United Kingdom  
United Kingdom  
United Kingdom  
United Kingdom  
United States  
United States  
United States

Zambia  
Zambia  
Zimbabwe

## Oversight Authority Organization Name

Ministry of Public Health  
Ministry of Health  
Human Research Bioethics Committee  
Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica  
Department of Health and Ageing Therapeutic Goods Administration  
Human Research Ethics Committee  
National Health and Medical Research Council  
Ethikkommission  
Agency for Health and Food Safety  
Federal Ministry for Health and Women  
Federal Office for Safety in Health Care  
Bangladesh Medical Research Council  
Directorate of Drug Administration  
Ethical Review Committee  
Ministry of Health  
Institutional Review Board  
Directorate general for the protection of Public health: Medicines  
Federal Agency for Medicinal Products and Health Products  
Ministry of Social Affairs, Public Health and the Environment  
The Federal Public Service (FPS) Health, Food Chain Safety and Environment  
Ethics Committee  
Ministry of Health  
National Health Surveillance Agency  
Ministry of Health  
National Committee of Ethics in Research  
Ministry of Health  
Bulgarian Drug Agency  
Ministry of Health  
Ministry for Higher Education and Research  
Ministry of Health  
Ministry of Public Health  
Canadian Institutes of Health Research  
Ethics Review Committee  
Health Canada  
Ministry of Health & Long Term Care, Ontario  
Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica  
Instituto de Salud Publica de Chile  
Ethics Committee  
Ministry of Health  
State Food and Drug Administration  
INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos  
  
Institutional Review Board  
Minister of Science, Education and Sports

Ministry of Health and Social Care  
Ethics Committee  
State Institute for Drug Control  
Danish Dataprotection Agency  
Danish Medicines Agency  
Ethics Committee  
National Board of Health  
The Danish National Committee on Biomedical Research Ethics  
The Ministry of the Interior and Health  
The Regional Committee on Biomedical Research Ethics  
Secretaría del Estado de Salud Pública y Asistencia Social (SESPAS)

Public Health Ministry  
Institutional Review Board  
Ministry of Health and Population  
The State Agency of Medicine  
Ethiopia Science and Technology Commission  
Ethics Committee  
Ministry of Social Affairs and Health  
National Agency for Medicines  
Afssaps - French Health Products Safety Agency  
Direction Générale de la Santé  
French Data Protection Authority  
Institutional Ethical Committee  
Ministry of Health  
National Consultative Ethics Committee for Health and Life Sciences  
Department of State for Health and Social Welfare  
MRC Ethics Committee  
Ministry of Health  
Federal Ministry of Food, Agriculture and Consumer Protection  
Federal Ministry of Education and Research  
Federal Institute for Drugs and Medical Devices  
Ethics Commission  
Paul-Ehrlich-Institut  
Committee on Human Research  
Ministry of Health  
National Organization of Medicines  
Ethics Committee  
Ministry of Health and Welfare  
Ministry of Health  
Joint CUHK-NTEC Clinical Research Ethics Committee  
Ethics Committee  
Department of Health  
National Institute of Pharmacy  
Ministry of Health and Social Security  
Icelandic Medicines Control Agency  
Science and Engineering Research Council  
Institutional Review Board

Ministry of Science and Technology  
Ministry of Health  
Department of Atomic Energy  
Drugs Controller General of India  
Indian Council of Medical Research  
Ministry of Health  
Medical Ethics Research Committee  
Irish Medicines Board  
Ethics Commission  
Ministry of Health  
Israeli Health Ministry Pharmaceutical Administration  
The Israel National Institute for Health Policy Research and Health  
Ministry of Health  
National Monitoring Centre for Clinical Trials - Ministry of Health  
Ethics Committee  
National Institute of Health  
National Bioethics Committee  
The Italian Medicines Agency  
Ministry of Health  
Foundation for Biomedical Research and Innovation  
Pharmaceuticals and Medical Devices Agency  
Ministry of Health, Labor and Welfare  
Ministry of Education, Culture, Sports, Science and Technology  
Institutional Review Board  
Ethical Committee  
Ethical Commission  
Ethical Review Committee  
Institutional Review Board  
Ministry of Health  
State Agency of Medicines  
Ministry of Public Health  
Institutional Review Board  
Control Authority for Medicinal Products  
Bioethics Committee  
State Medicine Control Agency - Ministry of Health  
Ethics Committee  
National Health Sciences Research Committee  
College of Medicine Research and Ethics Committee  
Ministry of Health  
Ministry of Health  
Ministry of Health and Quality of Life  
National Council of Science and Technology  
Ethics Committee  
Federal Commission for Protection Against Health Risks  
Ministry of Health  
National Institute of Public Health, Health Secretariat  
Federal Commission for Sanitary Risks Protection  
Ministry of Public Health

Ministry of Health (MISAU)  
The Central Committee on Research Involving Human Subjects (CCMO)

Dutch Health Care Inspectorate  
Medical Ethics Review Committee (METC)  
Medicines Evaluation Board (MEB)  
Independent Ethics Committee  
Health Research Council  
Food Safety Authority  
Health and Disability Ethics Committees  
Institutional Review Board  
Medsafe  
The National Agency for Food and Drug Administration and Control  
Data Inspectorate  
The National Committees for Research Ethics in Norway  
Norwegian Medicines Agency  
Norwegian Institute of Public Health  
Directorate for Health and Social Affairs  
Norwegian Social Science Data Services  
Ministry of Health  
Research Ethics Committee  
Ministry of Health  
Ethics Committee  
Ministry of Health  
General Directorate of Pharmaceuticals, Devices, and Drugs  
Bureau of Food and Drugs  
Department of Health  
Ministry of Scientific Research and Information Technology  
Drug Institute  
Ministry of Health  
Office for Registration of Medicinal Products, Medical Devices and  
Biocidal Products  
Ethics Committee for Clinical Research  
National Pharmacy and Medicines Institute  
Health Ethic Committee  
National Medicines Agency  
State Institute for Drug Control  
Research Advisory Council  
Ministry of Health  
Ministere de la sante  
Ethics Committee  
Ministry of Health and Sanitation  
Health Sciences Authority  
Domain Specific Review Boards  
Clinical Trials & Epidemiology Research Unit (CTERU)  
Agency for Medicinal Products - Ministry of Health  
Ministry of Health  
National Health Research Ethics Council

Medicines Control Council  
Department of Health  
Ministry of Health  
Spanish Agency of Medicines  
Ministry of Health and Consumption  
Comit? ?tico de Investigaci?n Cl?nica  
Ethics Committee  
Ministry of Healthcare & Nutrition  
Ministry of Health  
Medical Products Agency  
The National Board of Health and Welfare  
Swedish National Council on Medical Ethics  
Regional Ethical Review Board  
Institutional Review Board  
Ethikkommision  
Federal Office of Public Health  
Swissmedic  
Laws and standards  
Department of Health  
National Bureau of Controlled Drugs  
Institutional Review Board  
National Institute for Medical Research  
Food & Drug Administration  
Ministry of Health  
Ethical Committee  
Khon Kaen University Ethics Committee for Human Research  
Food and Drug Administration  
Ministry of Public Health  
Office of Pharmacies and Medicines  
Ministry of Public Health  
Ethics Committee  
Ministry of Health  
Research Ethics Committee  
Ministry of Health  
National Council for Science and Technology  
State Pharmacological Center - Ministry of Health  
Ministry of Health  
General Authority for Health Services for Abu Dhabi  
Drug Control Department - Medicines and Pharmacy Control - Ministry of Health  
Food Standards Agency  
Medicines and Healthcare Products Regulatory Agency  
Research Ethics Committee  
National Health Service  
Department of Health  
Federal Government  
Institutional Review Board  
Food and Drug Administration

Research Ethics Committee  
Ministry of Health  
Medical Research Council